Who are IV Novolin R human insulin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iv-novolin-r-human-insulin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

IV Novolin R human insulin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IV Novolin R human insulin (IV Novolin R human insulin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin, rapid-acting human insulin. Area: Diabetes.

marketed Insulin, rapid-acting human insulin Insulin receptor (INSR) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

IV Novolin R human insulin (IV Novolin R human insulin) — State University of New York - Downstate Medical Center. Novolin R is a rapid-acting human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IV Novolin R human insulin TARGET	IV Novolin R human insulin	State University of New York - Downstate Medical Center	marketed	Insulin, rapid-acting human insulin	Insulin receptor (INSR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin, rapid-acting human insulin class)

State University of New York - Downstate Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IV Novolin R human insulin — Competitive Intelligence Brief. https://druglandscape.com/ci/iv-novolin-r-human-insulin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab